Persistent Response and Prolonged Survival Following Pembrolizumab Discontinuation Due to Long-Lasting Autoimmune Colitis in Advanced NSCLC: A Case Report

Pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor that has been approved for treatment of a wide variety of malignancies including non-small-cell lung cancer (NSCLC). Immune-mediated colitis is a known adverse effect of pembrolizumab which can lead to the treatment interruption, althou...

Descripción completa

Detalles Bibliográficos
Autores principales: Damato, Angela, De Marco, Loredana, Serra, Silvia, Larocca, Mario, Arias, Alicia Garcia, Rondini, Ermanno, Pinto, Carmine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248363/
https://www.ncbi.nlm.nih.gov/pubmed/34221986
http://dx.doi.org/10.3389/fonc.2021.670415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248363/
https://www.ncbi.nlm.nih.gov/pubmed/34221986
http://dx.doi.org/10.3389/fonc.2021.670415

Ejemplares similares